| 5-HT1A | Serotonin receptor type 1A |
| ACF | Aberrant crypt foci |
| AD | Alzheimer’s disease |
| Aᵦ42 | Amiloid beta 42 |
| BCE | Before Common Era |
| BRCA-1 | Breast cancer gene 1 |
| BRCA-2 | Breast cancer gene 2 |
| cAMP | Cyclic adenosine monophosphate |
| CB1, CB2 | Cannabinoid receptor 1,2 |
| CBD | Cannabidiol |
| CBR | Cannabinoid receptor |
| CD-1; 4 | Cluster of differentiation 1; 4 |
| CGS | Glioma stem cells |
| CID 16020046 | Inverse agonist at the former orphan receptor GPR55 |
| COX | Cyclooxygenase |
| CT | Computed tomography scan |
| CXCL16 | Chemokine (C-X-C motif) ligand 16 |
| DNA | Deoxyribonucleic acid |
| EAE | Experimental autoimmune encephalomyelitis |
| EC50 | Half maximal effective concentration |
| EGF/EGFR | Epidermal growth factor/epidermal growth factor receptor |
| ELISA | Enzyme-linked immunosorbent assay |
| EMA | European Medicine Agency |
| EMV | Exosome and microvesicle |
| ENT-1 | Equilibrative nucleoside transporter-1 |
| ET-1 | Endothelin-1 |
| FDA | Food and Drug administration |
| GABA | Gamma-aminobutyric acid |
| GI | Gastro-intestinal |
| GPR55 | G-coupled protein receptor-55 |
| GSC | Glioma stem cell |
| GW9662 | Potent antagonist of Peroxisome proliferator-activated receptor gamma |
| GPX | Glutathione peroxidase |
| HUVEC | Human umbilical vein endothelial cells |
| HIF-1a | Regulatory subunit of the hypoxia- inducible transcription factor |
| i.p. | Intraperitoneal |
| IC50 | Half maximal inhibitory concentration |
| ICAM | Inter-intracellular adhesion molecule |
| ICR | Institute of Cancer Research |
| IFN-γ | Interferon Gamma |
| IGHM | Immunoglobulin heavy constant Mu |
| IL-2,6,8,9,12,IL-1A; 17A/F2 | Interleukin 2, 6,8,9,12, 1A, 17A/F2, |
| iNOS | Inducible nitric oxide synthase |
| Ki | Inhibitory constant binding affinity |
| KPC | KRAS, p53, Cre mice |
| MDA | Malonaldehyde |
| MIP-1α,1ᵦ,2 | Macrophage inflammatory protein 1α,1ᵦ, 2 |
| MMP2,9 | Matrix metalloproteinase-2, 9 |
| mRNA | Messenger RNA |
| Mtor | Mammalian target of rapamycin |
| NFκB | Nuclear factor κB |
| n.d. | Not determined |
| PAI-1 | Plasminogen activator inhibitor-1 |
| PDGF-AA | Platelet-derived growth factor subunit A |
| PERK | Extracellular signal-regulated kinase phosphorylation |
| Phospho-Akt | Phosphorylated AKT |
| PPARγ | Nuclear peroxisome proliferation activated receptor |
| PSA | Prostate-specific antigen |
| PTEN | Phosphatase and tensin homolog |
| ROS | Reactive oxygen species |
| RT-PRC | Real-time polymerase chain reaction |
| s.c. | Sub cutaneous |
| S100A10B | S100 calcium-binding protein A10 |
| S1P | Sphingosine-1-phosphate |
| S1PR1 | Sphingosine-1-phosphate receptor 1 |
| Serpin E1 | Serpin Family E Member 1 |
| SGPL1 | Sphingosine-1 phosphate lyase |
| SiRNA | Small interfering RNA |
| SOD | Superoxide dismutase |
| STAT-3,5 | Signal transducers and activators of transcription 3,5 |
| TGFBA | Transforming growth factor beta, alpha |
| THC | Tetrahydrocannabinol |
| THCA | Tetrahydrocannabinolic acid |
| TIMP1 | Tissue inhibitor of matrix metalloproteinases1 |
| TNF-α | Tumor necrosis factor α |
| Tp53 | Tumor protein p53 |
| TRP | Transient receptor potential |
| TRPA | Transient receptor potentialankyrin |
| TRPV1 | Transient receptor potential vanilloid type1 |
| TRPV2 | Transient receptor potential vanilloid type 2 |
| TRPM8 | Transient receptor potentialmelastatin 8 |
| uPA | Urokinase-type plasminogen activator |
| VEGF | Vascular endothelial growth factor |
| VR1, VR2 | Vanilloid receptor 1, 2 |